SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study

Key Takeaways Summit stock fell 25% after new HARMONi data on its lung cancer drug ivonescimab.Western patients saw a 33% risk reduction, compared with 45% for Asian patients.The FDA has indicated a significant OS benefit is required for drug approval.Shares of Summit Therapeutics (SMMT) tanked 25% yesterday after it reported a final analysis of data from the HARMONi study, which evaluated its investigational antibody ivonescimab in certain patients with non-small cell lung cancer (NSCLC).This analysis show ...